



Supported by



**Queen Mary Bioenterprises
BIOTECH INVESTMENT FORUM
9 am – 8pm, 5th October 2011**

Background

The QMB Biotechnology Investment Forum (QMB BIF) will be an annual unique one day forum exclusively focussing on the most promising private early-stage companies in the biotechnology industry.

The Forum is initiated by Queen Mary Bioenterprises Innovation Centre (QMB Innovation Centre) & Queen Mary Innovation on the 5th October 2011 and hosted at QMB Innovation Centre.

It will bring together new start-up companies from across the UK along with venture capital (VC) organisations that invest in early-stage companies

Circa 10-15 companies from across the UK (including some tenants located on site) will present to 20+ investment companies. Members of the Medical School & Queen Mary Innovation are asked attend, either to explore potential company connections, or to further understand the funding and research priorities for early-stage bioscience organisations.

The Forum provides an opportunity to publicise and promote the campus resources, to be a conduit for deal-making and to allow Institute scientists to see the VC-biomedical company interactions and promote the grow-on incubation space facilities at Queen Mary University. This also provides an opportunity for SME's to get exposed to the Institute and of course funders. Further having exposure to the investment process helps build upon the entrepreneurial culture we are seeking here and as part of the London Cluster.

The Investment Forum hopes to be the leading London based Biotech investor event of the year.

Focus

The Biotech Forum will focus on early stage ventures, & companies seeking seed stage investment and series A financing.

Early stage investment has always been seen as an exciting, but risky alternative asset class, but set in the context of today's market turmoil, its relative risk profile is altered. These businesses are perfectly poised to exploit their market opportunities as more established players divert resources to deal with the effects of the credit crunch.

Early stage investors & business angels from across Europe will examine over 15 investment pitches at QMB, from young technology businesses across the UK.

The message from the Forum is that the opportunities open to early stage investors for both private investors and venture capitalists are as good as ever.

Format

The format of the forum will be a mixture of two pitching sessions (am = up to £1M, pm = series A financing), an introductory session which will look at "thin markets" and the early stage funding gap, a Q&A session at the end of the day, which will look at some of the issues facing the later stage end of Biotech (namely M&A & late stage financings) followed by drinks and canapé evening session.
Two sector focus, across medtech and biotech.

The Introductory Welcome Session: "Thin markets & the early stage funding gap"

Chair/Host – Jennifer Harris, Partner, Kilburn & Strode LLP

Rowan Gardner Astia/BioLauncher

Andrew Muir – Midven/Rainbow Seed Fund/Early Advantage Fund

Sunil Shah Founder, O2H

Deborah Harland- Partner, SR One

**Kilburn
& Strode**

Closing Panel Session: "Late stage Biotech Financing & M&A"

Chair- Francis Doherty, Partner, Dorsey & Whitney LLP

Kate Bingham- Managing Partner, SV Life Sciences

Anders Knutson, Vice President, Credit Suisse

Sacha Mann, Investment Manager, Inventages

Dean Slagel, Managing Director, Esperante Ventures

Kaasim Mahmood, Partner, Advent Venture Partners



SCRIP – One Nucleus BioWednesday Debate

"Does the UK need to create more public life science companies?"

Chair – Mike Ward, Editor, Scrip Intelligence

Panellists thus far confirmed as follows:

Cléa Rosenfeld, ex-Head of Investor Relations, Shire Pharmaceuticals

Nigel Gaymond, CEO, BiIndustry Association

Ken Powell, Chairman, Q-Chip

Jacob Thrane, Standard & Poor

Alan Edwards, Chairman, Asep Healthcare

SCRIP

Confirmed & growing list of attending Investors...:



wellingtonpartners
VENTURE CAPITAL

ev²TECH

SR-one

Gilde

ipgroup_{plc}

cambridge enterprise
commercialising University science



mercia fund management

midven

funding for growth companies



Scottish Enterprise



Entrepreneurs Fund
GROW IN GOOD COMPANY